TransCode Therapeutics Inc
RNAZ
Company Profile
Business description
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company’s lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Contact
6 Liberty Square
No. 2382
BostonMA02109
USAT: +1 857 837-3099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,298.20 | 10.30 | 0.12% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,425.83 | 154.16 | 0.69% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 21,926.26 | 81.85 | -0.37% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 35,902.51 | 62.52 | 0.17% |
| NZX 50 Index | 11,974.35 | 51.10 | -0.42% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,083.30 | 12.70 | 0.16% |
| SSE Composite Index | 3,281.49 | 5.17 | -0.16% |